@prefix : <http://www.s-cubed.dk/ZINVESTDEV_T2DM/V1#> .
@prefix pr: <http://www.assero.co.uk/Protocol#> .
@prefix isoC: <http://www.assero.co.uk/ISO11179Concepts#> .
@prefix isoT: <http://www.assero.co.uk/ISO11179Types#> .
@prefix isoR: <http://www.assero.co.uk/ISO11179Registration#> .
@prefix isoI: <http://www.assero.co.uk/ISO11179Identification#> .
@prefix bo: <http://www.assero.co.uk/BusinessOperational#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .

<http://www.s-cubed.dk/ZINVESTDEV_T2DM/V1>
	rdf:type owl:Ontology ;
.
<http://www.assero.co.uk/EP#ff05d0b6-b17d-4f2a-93b4-26dde5e831f6>
	rdf:type pr:Epoch ;
	isoC:label "Screening"^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/EP#63255898-45b1-4a47-a898-6dec994670ba>
	rdf:type pr:Epoch ;
	isoC:label "Supportive Care | Exercise-led Phase"^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/EP#a00358bc-83f7-4c82-9692-97e4d83c3315>
	rdf:type pr:Epoch ;
	isoC:label "Follow-Up | Home-based Phase"^^xsd:string ;
	pr:ordinal "3"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#e3d05d4c-f6a4-4852-ae63-f6f4cce40991>
	rdf:type pr:Arm ;
	isoC:label "rtCGM"^^xsd:string ;
	pr:description "Real-time Continuous Glucose Monitoring"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#01bcddd7-4e5a-424e-876a-49d292b034b8>
	rdf:type pr:Arm ;
	isoC:label "isCGM"^^xsd:string ;
	pr:description "Intermittent scan (flash) Continuous Glucose Monitoring"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ELE#515079cf-05e0-4bd4-acf0-ebec118f069d>
	rdf:type pr:Element ;
	isoC:label "Screening"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#e3d05d4c-f6a4-4852-ae63-f6f4cce40991> ;
	pr:inEpoch <http://www.assero.co.uk/EP#ff05d0b6-b17d-4f2a-93b4-26dde5e831f6> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
.
<http://www.assero.co.uk/ELE#cd3c8c80-be7a-4380-9f16-af12e9f7d25e>
	rdf:type pr:Element ;
	isoC:label "Screening"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#01bcddd7-4e5a-424e-876a-49d292b034b8> ;
	pr:inEpoch <http://www.assero.co.uk/EP#63255898-45b1-4a47-a898-6dec994670ba> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
.
<http://www.assero.co.uk/ELE#99520077-9a63-452e-a9a4-334ced06c077>
	rdf:type pr:Element ;
	isoC:label "Exercise Led Phase"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#e3d05d4c-f6a4-4852-ae63-f6f4cce40991> ;
	pr:inEpoch <http://www.assero.co.uk/EP#63255898-45b1-4a47-a898-6dec994670ba> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#78a97787-41c6-4aa7-a2d9-175b46a28f99> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#0530b547-7831-4a9e-8aa8-2e49eb8fef2f> ;
.
<http://www.assero.co.uk/ELE#a1d9f61a-4dfd-45aa-9f4d-2ba7c140be6d>
	rdf:type pr:Element ;
	isoC:label "Exercise Led Phase"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#01bcddd7-4e5a-424e-876a-49d292b034b8> ;
	pr:inEpoch <http://www.assero.co.uk/EP#63255898-45b1-4a47-a898-6dec994670ba> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#78a97787-41c6-4aa7-a2d9-175b46a28f99> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#0530b547-7831-4a9e-8aa8-2e49eb8fef2f> ;
.
<http://www.assero.co.uk/ELE#1e60eb0f-cc4e-4457-aba5-4e3ba7f8d3e5>
	rdf:type pr:Element ;
	isoC:label "Home-based Phase"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#e3d05d4c-f6a4-4852-ae63-f6f4cce40991> ;
	pr:inEpoch <http://www.assero.co.uk/EP#a00358bc-83f7-4c82-9692-97e4d83c3315> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#ed1ef0bb-e8c6-4c0c-8626-d0b2cdc6e54f> ;
.
<http://www.assero.co.uk/ELE#a66a6fef-484f-4b5a-84be-52c5b7b6c28b>
	rdf:type pr:Element ;
	isoC:label "Home-based Phase"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#01bcddd7-4e5a-424e-876a-49d292b034b8> ;
	pr:inEpoch <http://www.assero.co.uk/EP#a00358bc-83f7-4c82-9692-97e4d83c3315> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#ed1ef0bb-e8c6-4c0c-8626-d0b2cdc6e54f> ;
.
:PR
	rdf:type pr:Protocol ;
	isoC:label "ZINVESTDEV Type 2 Diabetes"^^xsd:string ;
	isoT:hasState :PR_RS ;
	isoT:hasIdentifier :PR_SI ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2021-03-12T17:14:21+01:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "ZINVESTDEV T2"^^xsd:string ;
	pr:title "The aim of this investigator's study is to compare real-time continuous glucose monitoring (rtCGM) and flash glucose monitoring (isCGM) in adult patients with Type 1 or Type 2 Diabetes during a 14-day training program focused on physical activity and over 4 or 6 weeks of follow-up at home"^^xsd:string ;
	pr:shortTitle "ZINVESTDEV"^^xsd:string ;
	pr:studyPhase :PR_TUC3 ;
	pr:studyType :PR_TUC4 ;
	pr:interventionModel :PR_TUC1 ;
	pr:masking :PR_TUC2 ;
	pr:forIndication <http://www.s-cubed.dk/IND_TYPE_2_DIABETES_MELLITUS/V1#IND> ;
	pr:inTa <http://www.s-cubed.dk/TA_M/V1#TA> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#e3d05d4c-f6a4-4852-ae63-f6f4cce40991> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#01bcddd7-4e5a-424e-876a-49d292b034b8> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#ff05d0b6-b17d-4f2a-93b4-26dde5e831f6> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#63255898-45b1-4a47-a898-6dec994670ba> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#a00358bc-83f7-4c82-9692-97e4d83c3315> ;
	pr:specifiesObjective <http://www.assero.co.uk/PROBJ#02d93bf7-d3c1-4308-92f7-abcd3747fc31> ;
	pr:specifiesObjective <http://www.assero.co.uk/PROBJ#69263278-d4bc-49c6-a010-0d73d9fb7555> ;
	pr:specifiesObjective <http://www.assero.co.uk/PROBJ#f459711d-dbd2-434b-8865-5204a94f1682> ;
	pr:specifiesObjective <http://www.assero.co.uk/PROBJ#3d08e15c-9c89-4302-aac5-73ca847fc420> ;
.
:PR_RS
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS123456789> ;
.
:PR_SI
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "ZINVESTDEV T2DM"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#SCUBED> ;
.
:PR_TUC3
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V38#C66737_C48660> ;
	bo:context <http://www.cdisc.org/CT/V68#TH> ;
	bo:localLabel ""^^xsd:string ;
.
:PR_TUC4
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V68#TH> ;
	bo:localLabel ""^^xsd:string ;
.
:PR_TUC1
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99076/V55#C99076_C82639> ;
	bo:context <http://www.cdisc.org/CT/V68#TH> ;
	bo:localLabel ""^^xsd:string ;
.
:PR_TUC2
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:context <http://www.cdisc.org/CT/V68#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.assero.co.uk/VI#43a4674c8dbb9a7a54fca337c8685f379ae67724>
	rdf:type pr:Visit ;
	isoC:label "Run-in"^^xsd:string ;
	pr:shortName "Vis#01"^^xsd:string ;
.
<http://www.assero.co.uk/VI#26b1c771fb3760f35a954cc6f948de851dfae630>
	rdf:type pr:Visit ;
	isoC:label "Baseline"^^xsd:string ;
	pr:shortName "Vis#02"^^xsd:string ;
.
<http://www.assero.co.uk/VI#24dc77d16170cb26034f547e8b7ac56f1a0f2a13>
	rdf:type pr:Visit ;
	isoC:label "Week 1"^^xsd:string ;
	pr:shortName "Vis#03"^^xsd:string ;
.
<http://www.assero.co.uk/VI#3ea4f410ece4b621097a543af2a7097e53ef1f95>
	rdf:type pr:Visit ;
	isoC:label "Week 2"^^xsd:string ;
	pr:shortName "Vis#04"^^xsd:string ;
.
<http://www.assero.co.uk/VI#d75c7fe12a17dd078cf0c882a4005b67d538b0bb>
	rdf:type pr:Visit ;
	isoC:label "Week 6"^^xsd:string ;
	pr:shortName "Vis#05"^^xsd:string ;
.
<http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d>
	rdf:type pr:Timepoint ;
	isoC:label "TP1"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#TPO_ea3e5bff-13e0-4eb2-b16d-5617ed33b904> ;
	pr:inVisit <http://www.assero.co.uk/VI#43a4674c8dbb9a7a54fca337c8685f379ae67724> ;
.
<http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210>
	rdf:type pr:Timepoint ;
	isoC:label "TP2"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#TPO_257f0856-a913-496b-a532-c9309b1dbf0c> ;
	pr:inVisit <http://www.assero.co.uk/VI#26b1c771fb3760f35a954cc6f948de851dfae630> ;
.
<http://www.assero.co.uk/TP#78a97787-41c6-4aa7-a2d9-175b46a28f99>
	rdf:type pr:Timepoint ;
	isoC:label "TP3"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#TPO_59684f5a-cadf-4ebb-abfb-fea54e671cbb> ;
	pr:inVisit <http://www.assero.co.uk/VI#24dc77d16170cb26034f547e8b7ac56f1a0f2a13> ;
.
<http://www.assero.co.uk/TP#0530b547-7831-4a9e-8aa8-2e49eb8fef2f>
	rdf:type pr:Timepoint ;
	isoC:label "TP4"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#TPO_d42d447e-e5dc-4948-a0b0-c77949aacc2d> ;
	pr:inVisit <http://www.assero.co.uk/VI#3ea4f410ece4b621097a543af2a7097e53ef1f95> ;
.
<http://www.assero.co.uk/TP#ed1ef0bb-e8c6-4c0c-8626-d0b2cdc6e54f>
	rdf:type pr:Timepoint ;
	isoC:label "TP5"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#TPO_649fcc26-27bd-4383-b953-30d7627e949e> ;
	pr:inVisit <http://www.assero.co.uk/VI#d75c7fe12a17dd078cf0c882a4005b67d538b0bb> ;
.
<http://www.assero.co.uk/IC#TPO_ea3e5bff-13e0-4eb2-b16d-5617ed33b904>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "-604800"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Day"^^xsd:string ;
.
<http://www.assero.co.uk/IC#TPO_257f0856-a913-496b-a532-c9309b1dbf0c>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "604800"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Day"^^xsd:string ;
.
<http://www.assero.co.uk/IC#TPO_59684f5a-cadf-4ebb-abfb-fea54e671cbb>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "4233600"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Day"^^xsd:string ;
.
<http://www.assero.co.uk/IC#TPO_d42d447e-e5dc-4948-a0b0-c77949aacc2d>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "8467200"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Day"^^xsd:string ;
.
<http://www.assero.co.uk/IC#TPO_649fcc26-27bd-4383-b953-30d7627e949e>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "25401600"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Day"^^xsd:string ;
.
<http://www.assero.co.uk/PROBJ#02d93bf7-d3c1-4308-92f7-abcd3747fc31>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ1"^^xsd:string ;
	pr:fullText "To assess the effect of Xanomeline Transdermal Therapeutic System (TTS) on the ADAS-Cog and CIBIC+ scores at Week 24 in participants with Mild to Moderate Alzheimer’s Disease"^^xsd:string ;
	pr:derivedFromObjective <http://www.s-cubed.dk/OBJ_1/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#b8c02137-d8d4-4f5a-bfe5-2f190f5bb094> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#64f2725b-c04e-40c2-a10d-4020a19337aa> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
.
<http://www.assero.co.uk/PROBJ#69263278-d4bc-49c6-a010-0d73d9fb7555>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ2"^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas"^^xsd:string ;
	pr:derivedFromObjective <http://www.s-cubed.dk/OBJ_3/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#af70f70f-b3bc-4652-99c7-9886ac599349> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
.
<http://www.assero.co.uk/PROBJ#f459711d-dbd2-434b-8865-5204a94f1682>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ3"^^xsd:string ;
	pr:fullText "To document the safety profile of the xanomeline TTS."^^xsd:string ;
	pr:derivedFromObjective <http://www.s-cubed.dk/OBJ_4/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#2ca1a839-0636-4827-a73f-018bd5f71cbe> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#e7303e43-45d9-40cc-aeb1-cd13984b268e> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#e75a85f6-8382-49c7-83ee-d5e81d41e100> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#4e02ec15-b550-4981-a41e-a23be64da005> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#b710a1f98200b22b534bf1269c5fa2c84e1b6d82> ;
.
<http://www.assero.co.uk/PROBJ#3d08e15c-9c89-4302-aac5-73ca847fc420>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ4"^^xsd:string ;
	pr:fullText "To assess the effect of xanomeline TTS on the measure of behavioral/neuropsychiatric symptoms in participants with  Alzheimer’s Disease"^^xsd:string ;
	pr:derivedFromObjective <http://www.s-cubed.dk/OBJ_5/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#8ba6ac85-b1d3-4f97-a339-8a78534923a4> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#b710a1f98200b22b534bf1269c5fa2c84e1b6d82> ;
.
<http://www.assero.co.uk/PROBJ#2699179e-8376-436d-9b2b-881e52c9059e>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ5"^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas"^^xsd:string ;
	pr:derivedFromObjective <http://www.s-cubed.dk/OBJ_6/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#c6627fa2-4253-4792-9a06-6fce953def3f> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#b710a1f98200b22b534bf1269c5fa2c84e1b6d82> ;
.
<http://www.assero.co.uk/PREND#b8c02137-d8d4-4f5a-bfe5-2f190f5bb094>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP1"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Alzheimer’s Disease Assessment Scale – Cognitive Assessment (ADAS-Cog) 14 total score"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_1/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0530b547-7831-4a9e-8aa8-2e49eb8fef2f> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#ed1ef0bb-e8c6-4c0c-8626-d0b2cdc6e54f> ;
.
<http://www.assero.co.uk/PREND#64f2725b-c04e-40c2-a10d-4020a19337aa>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP2"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+)"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_2/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0530b547-7831-4a9e-8aa8-2e49eb8fef2f> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#ed1ef0bb-e8c6-4c0c-8626-d0b2cdc6e54f> ;
.
<http://www.assero.co.uk/PREND#af70f70f-b3bc-4652-99c7-9886ac599349>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP3"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_9/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
.
<http://www.assero.co.uk/PREND#2ca1a839-0636-4827-a73f-018bd5f71cbe>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP4"^^xsd:string ;
	pr:fullText "The proportion of participants with adverse events, serious adverse events (SAEs), and adverse events leading to study intervention discontinuation over the 24-week study intervention period"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_5/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#ed1ef0bb-e8c6-4c0c-8626-d0b2cdc6e54f> ;
.
<http://www.assero.co.uk/PREND#e7303e43-45d9-40cc-aeb1-cd13984b268e>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP5"^^xsd:string ;
	pr:fullText "The change from baseline to Week 12 in continuous laboratory tests: Hepatic Function Panel"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_6/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#78a97787-41c6-4aa7-a2d9-175b46a28f99> ;
.
<http://www.assero.co.uk/PREND#e75a85f6-8382-49c7-83ee-d5e81d41e100>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP6"^^xsd:string ;
	pr:fullText "The proportion of participants with abnormal (high or low) laboratory measures (urinalysis) during the postrandomization phase"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_7/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#78a97787-41c6-4aa7-a2d9-175b46a28f99> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0530b547-7831-4a9e-8aa8-2e49eb8fef2f> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#ed1ef0bb-e8c6-4c0c-8626-d0b2cdc6e54f> ;
.
<http://www.assero.co.uk/PREND#4e02ec15-b550-4981-a41e-a23be64da005>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP7"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in ECG parameter: QTcF"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_8/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
.
<http://www.assero.co.uk/PREND#8ba6ac85-b1d3-4f97-a339-8a78534923a4>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP8"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_9/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
.
<http://www.assero.co.uk/PREND#c6627fa2-4253-4792-9a06-6fce953def3f>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP9"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the DAD total score"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.s-cubed.dk/EP_9/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#f50e2f50-964e-4b52-9804-618365d4272d> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#2cdfcb84-b640-4e04-96a3-e5fbb7291210> ;
.